Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,433.00+0.82%ETH$2,480.72+0.28%GOLD$4,220.50+1.53%OIL$91.61+0.13%
Smart Investors Daily
SID Premium
VR

NASDAQ · VRCA

Verrica Pharmaceuticals Inc.

Healthcare · Biotechnology

$4.18

Down-$0.07 (-1.67%)

Updated Oct 9, 2026, 9:00 PM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
79.81M
P/E ratio
-3.07
Dividend yield
0.00%
52-week range
$4.05 – $8.50
Volume
37.19K
Avg. volume
399.36K

Price performance · VRCA

VRCA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 8, 2026

VRCA closed at $4.18 after 21 trading sessions, down 15.56% for the selected period.

Last close
$4.18
Period change
-15.56%
Period low
$4.14
Period high
$4.95
Daily close
View OHLC price history
VRCA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 8, 2026$4.14$4.29$4.05$4.1837.19K
Oct 7, 2026$4.15$4.3299$4.06$4.1447.65K
Oct 6, 2026$4.36$4.41$4.17$4.2141.31K
Oct 5, 2026$4.34$4.5387$4.25$4.3135.04K
Oct 2, 2026$4.56$4.8434$4.37$4.3844.71K
Oct 1, 2026$4.85$4.85$4.515$4.51555.31K
Sep 30, 2026$4.51$5.04$4.51$4.79550.99K
Sep 29, 2026$4.67$4.67$4.4526$4.463.7K
Sep 28, 2026$4.33$4.63$4.32$4.6033.4K
Sep 25, 2026$4.39$4.50$4.36$4.3772.85K
Sep 24, 2026$4.62$4.6424$4.355$4.3640.9K
Sep 23, 2026$4.67$4.78$4.55$4.6241.33K
Sep 22, 2026$4.50$4.90$4.50$4.7265.14K
Sep 21, 2026$4.55$4.635$4.40$4.4929.59K
Sep 18, 2026$4.61$4.74$4.45$4.45114.16K
Sep 17, 2026$4.70$4.7899$4.57$4.6541.34K
Sep 16, 2026$4.66$4.695$4.53$4.5348.3K
Sep 15, 2026$4.75$4.77$4.5138$4.5846.44K
Sep 14, 2026$4.91$5.06$4.70$4.7843.1K
Sep 11, 2026$4.99$5.03$4.80$4.9141.89K
Sep 10, 2026$5.06$5.25$4.86$4.9556.97K

Latest VRCA news

The latest Smart Investors Daily articles mentioning VRCA.

Stock researchCompany · Overview

VRCA research

Overview

Company profile and research snapshot.

Company profile

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$12.00
Implied upside
—
Analysts
12
VRCA recent ratings
DateFirmRatingTarget
Dec 18, 2025Brookline CapitalBuy—
May 14, 2025NeedhamHold—
Apr 9, 2025NeedhamHold—
Apr 8, 2025HC Wainwright & Co.Neutral—
Mar 12, 2025NeedhamHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration – WEST CHESTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will present posters on a new analysis of Phase 3 trials of

Yahoo · Sep 10, 2026

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

– Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration – WEST CHESTER, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will present posters on YCANTH® (VP-102), a therapy approved by the FDA

Yahoo · Sep 8, 2026

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 28th Annual Global Investment Conference. H.C. Wainwright 28th Annual Global Investment ConferenceEvent d

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By